美国 · 平台与数据 · MarketBeat
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom

详细摘要
Vertex Pharmaceuticals (NASDAQ:VRTX) is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event. Susie Lisa, Vertex’s seni
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.marketbeat.com)




